InvestorRoom | Kitov Pharmaceuticals http://kitovpharma.investorroom.com/ TyrNovo to Present at 2018 Annual Meeting of the American Association for Cancer Research http://kitovpharma.investorroom.com/2018-04-13-TyrNovo-to-Present-at-2018-Annual-Meeting-of-the-American-Association-for-Cancer-Research Treatment with TyrNovo's NT219 in combination with targeted cancer drugs, as well as chemotherapy and immuno-oncology therapies, prevented acquired resistance and reversed resistance of colon, lung and head-and-neck cancers in patient-derived xenograft models Fri, 13 Apr 2018 09:21:00 -0400 http://kitovpharma.investorroom.com/2018-04-13-TyrNovo-to-Present-at-2018-Annual-Meeting-of-the-American-Association-for-Cancer-Research TyrNovo to Present at BIO-Europe SpringĀ® 2018 Conference http://kitovpharma.investorroom.com/2018-03-08-TyrNovo-to-Present-at-BIO-Europe-Spring-R-2018-Conference Treatment with TyrNovo's NT219 in combination with targeted cancer drugs, as well as chemotherapy and immuno-oncology therapies, prevented acquired resistance and reversed resistance of colon, lung and head-and-neck cancers in patient-derived xenograft models Thu, 08 Mar 2018 09:33:00 -0500 http://kitovpharma.investorroom.com/2018-03-08-TyrNovo-to-Present-at-BIO-Europe-Spring-R-2018-Conference Kitov Announces Consensiā„¢ as Brand Name for KIT-302 http://kitovpharma.investorroom.com/news-releases?item=59 Thu, 14 Dec 2017 09:44:00 -0500 http://kitovpharma.investorroom.com/news-releases?item=59 Kitov Pharmaceuticals Announces Receipt of FDA's Favorable Response to NT219's pre-IND Meeting Package http://kitovpharma.investorroom.com/2017-11-01-Kitov-Pharmaceuticals-Announces-Receipt-of-FDAs-Favorable-Response-to-NT219s-pre-IND-Meeting-Package TyrNovo to Initiate Clinical Development on Advanced Pancreatic Cancer Patients Wed, 01 Nov 2017 09:15:00 -0400 http://kitovpharma.investorroom.com/2017-11-01-Kitov-Pharmaceuticals-Announces-Receipt-of-FDAs-Favorable-Response-to-NT219s-pre-IND-Meeting-Package Kitov Pharmaceuticals Announces Phase III/IV Clinical Trial for KIT-302 Successfully Meets Primary Endpoint, and also Demonstrates Drug Candidate Improves Renal Function http://kitovpharma.investorroom.com/Kitov-Pharmaceuticals-Announces-Phase-III-IV-Clinical-Trial-for-KIT-302-Successfully-Meets-Primary-Endpoint-and-also-Demonstrates-Drug-Candidate-Improves-Renal-Function Thu, 26 Oct 2017 14:00:00 -0400 http://kitovpharma.investorroom.com/Kitov-Pharmaceuticals-Announces-Phase-III-IV-Clinical-Trial-for-KIT-302-Successfully-Meets-Primary-Endpoint-and-also-Demonstrates-Drug-Candidate-Improves-Renal-Function